All In Biotech

Investigational drug · Phase 2

vilamakitug

Also called: XB2001, Natrunix

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

1

Any phase or sponsor naming "vilamakitug"

First trial start

2026

Jul 15, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "vilamakitug", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Axial Spondyloarthritis
  • Ankylosing Spondylitis
  • r-axSpA
  • Nr-axSpA
  • Rheumatoid Arthritis

Approved drugs for the same conditions: Rheumatoid arthritis · Ankylosing spondylitis · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "vilamakitug" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Axial Spondyloarthritis

  • FilgotinibGS-6034, GLPG0634Phase 36 trials

    Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)

  • SPY002-072SPY072Phase 22 trials

    Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.